secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001493152-23-014059
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences FY2022 net product sales $16.8M (+104% YoY); net loss $(78.0M)
--------------------------------------------------------------------------------

- Net product sales doubled to $16.8M in 2022 from $8.2M in 2021, driven by unit growth and promotional strategies.
- Total operating expenses cut 42% to $101.0M, exceeding the stated $50M cost reduction goal.
- Net loss attributable to common stockholders improved to $(78.0)M ($1.34/diluted share) from $(206.2)M ($23.63/share) in 2021.
- Cash at Dec 31, 2022: $2.8M unrestricted; raised $1.8M from senior secured convertible notes in Q1 2023.
- Appointed Ivy Zhang as CFO and Secretary effective April 13, 2023; targeting EBITDA break-even by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/0001493152-23-014059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-014059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer